NanoPhoria

Description

NanoPhoria develops an inhaled Nano-in-Micro delivery platform and formulations to deliver therapeutic peptides and RNAs for tissue-directed cardiovascular treatments, including an inhalable candidate for HFrEF.

NanoPhoria is located in the Milan ecosystem.

Related

• OrexoOrexo develops powder-based drug delivery technologies and therapeutic formulations, including AmorphOX®, used to improve bioavailability…
• Enterprise TherapeuticsEnterprise Therapeutics researches and develops respiratory disease therapies, including inhaled ENaC blocker ETD001, to address mucus…
• EVerZomEVerZom develops exosome therapeutics by combining proprietary manufacturing and formulation technologies for scalable, reproducible, and…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…
• InvitrolizeInvitrolize develops and applies advanced human-relevant in vitro respiratory models and provides the ALIsens® 3D alveolar assay to assess…
• HAYA TherapeuticsHAYA Therapeutics develops RNA-guided medicines that use functional genomics and computational tools to identify, target, and monitor…
• EnzyTagEnzyTag develops peptiligase-based synthetic routes for manufacturing peptide new chemical entities, small proteins, and peptide…
• Molecular PartnersMolecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and…